Media, page-134

First 134 Last

Share
Profile

Follow
Venge

2,247 Posts.

420

18/01/23

17:18

Post #: 65757845
Share

Originally posted by Mattycarcar: ↑

cut it out venge
spend your time trying to work out a better stock pick than GBR
down she goes captain. who is going down with the ship?

lets hope their maiden resource estimate is half decent
youve got a lot of discoverers already sitting on 1 million plus oz finds not worth a lot, pantorro rings a bell as does KAI

i dont trust patto comes across as a sketchy oil car salesman the more you watch his videos; the sweaty face and nervous responses.
gbr went from being the next big gold find in WA to just another high grade vein system 200 metres under the ground. they were expecting to strike it big remember when they drilled that DD into that anomoly... boy wasnt that a fizzer. turned up a dud. and now they are waffling on about ironabrk
and lithium now. they need to focus; its all over thr shop
and the collapsing shareprice shows it

the rats have already started swimming to shore, itll be a stampede for the exit UNLESS they get a good maiden estimate. Venge im sorry youve bought in and its headed down since you bought it. this isnt personal ive owned GBR before you were even on this GBR forum and saw the writing on the wall. this aint no deg or chalice; its just another gold discoverer trying to find an economical amount of dirt to dig up and they arent there yet

after their maiden estimate because its so deep they Re goijg to have to keep drilling to try and locate more high grade vein at mulga or they will have to find lower depth told loke at ironbark.

long way to go for this company and a lot more hand outs coming as they please for more money. venge you will come and go. see you on the flip side you vengful little ant

Expand

So many assumptions in your post you are not worth my time anymore. I’ve showed those who could be bothered just the type of individual you are, that’s all I needed to do. You can continue your post with your poor research whilst we can laugh at your expense.
PS what type of flex is putting me on ignore, go for it little man.

GBR Price at posting: 8.9¢ Sentiment: Hold Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

There are more pages in this discussion • 35 more messages in this thread...

First 134 Last

Add GBR (ASX) to my watchlist

(20min delay)
Last 5.6¢		Change -0.001(1.75%)		Mkt cap ! $34.12M

Open	High	Low	Value	Volume
5.7¢	5.7¢	5.6¢	$14.12K	250.3K

Buyers (Bids)

No.	Vol.	Price($)
2	21346	5.6¢

Sellers (Offers)

Price($)	Vol.	No.
5.7¢	73213	2

View Market Depth

No.	Vol.	Price($)
2	71346	0.056
2	211818	0.055
1	400271	0.054
2	1010000	0.053
2	107000	0.052

Price($)	Vol.	No.
0.057	73213	2
0.058	432724	2
0.059	500000	1
0.060	500000	2
0.062	10000	1

Last trade - 15.00pm 07/10/2024 (20 minute delay)

GBR (ASX) Chart

Media, page-134

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Media, page-134

Top Stories

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News